From Microarray to Bedside: Targeting NF-κB for Therapy of Lymphomas Available to Purchase

Progress in biomedical science often comes from the confluence of different avenues of investigation arriving at shared understandings and pointing to new directions. This is nowhere more apparent than in the development of molecular oncology, the application of molecular approaches to the study, treatment, and prevention of cancer. The confluence of viral oncogenesis and cancer genetics ultimately led to the development of imatinib and the pursuit of other targeted therapies. The confluence of understandings of the immune response and lymphoid malignancies have similarly opened new avenues. Recently, the application of sophisticated genomic and large-scale mRNA expression analysis to the study of lymphomas has fostered the development of new disease classifications that take advantage of evolving concepts in immunology. In this issue of Clinical Cancer Research, Lam et al. have extended studies from the Staudt laboratory to address the hypothesis that the NF-κB pathway, originally identified as a key signaling...